Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

NCT00734864 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.

Conditions

Interventions

Sponsor

Annick Desjardins

Collaborators